ZIOPHARM Oncology Культура компании

Dr. Francois Lebel, MD has been the Chief Medical Officer and Executive Vice President of Research & Development at ZIOPHARM Oncology, Inc. since February 2015. Dr. Lebel served as Senior Vice President of Clinical Development and Medical Operations at ZIOPHARM Oncology, Inc. Dr. Lebel is a proven leader with broad Drug and Device development experience who has designed and managed global medical organizations to deliver results, enhanced productivity and practice sound risk management. He served as Vice President of Research & Development at Baxter International and Global Head of Medical and Scientific Affairs at MedImmune. In the last 20 years, he provided strategic leadership on 8 NDA/BLA's in various therapeutic areas and on a number of mergers and acquisitions. He served as Vice President of Medical Affairs at MedImmune Inc., (alternate name MedImmune, LLC) since November 15, 2004. He oversaw MedImmune's medical activities relating to marketed products, including clinical trials and medical information. Dr. Lebel has more than 15 years of drug development experience, having played a key role in four new drug applications to the U.S. Food & Drug Administration. In addition, he has conducted several late-stage virology and oncology studies, including using patient registries to explore new indications. He gained extensive international experience from the launch of a number of products in more than 40 countries. Dr. Lebel has a strong record of accomplishments in a variety of increasingly responsible medical, regulatory and quality assurance positions held at Parke-Davis (Warner- Lambert), Galagen, Inc., and Burroughs Wellcome, Inc. In 2000, he joined PathoGenesis Corp., where he facilitated the company's integration with Chiron, becoming Chiron-Seattle General Manager. Most recently, he served as Divisional Vice President and Head of Global Medical Affairs at Chiron headquarters in Emeryville, California. He is Board Certified in Internal Medicine. Dr. Lebel holds Bachelor's and Medical Degrees from the University of Ottawa and trained in Microbiology and Infectious Diseases at McGill University and Harvard Medical School.

Mr. Caesar J. Belbel has been the Chief Legal Officer and Executive Vice President of ZIOPHARM Oncology, Inc. since September 6, 2011 and is responsible for ZIOPHARM's legal affairs. Mr. Belbel has been Secretary at ZIOPHARM Oncology, Inc. since September 6, 2011. Mr. Belbel served as the Chief Operating Officer at ZIOPHARM Oncology, Inc. since June 2015 until November 6, 2017. He served as Chief Legal Officer, Executive Vice President and Secretary at Avalon Pharmaceuticals, Inc. since May 2009. He served as Secretary of Programart Corporation and Astea International Inc. He served as the Chief Legal Officer of Clinical Data, Inc. and served as its Executive Vice President since October 2005 where he had been responsible for its all legal & regulatory affairs. He served as Secretary of Astea International Inc. Mr. Belbel served as Secretary of Clinical Data, Inc. since June 25, 2003 and then again served until April 13, 2011. He served as General Counsel and Vice President of Clinical Data, Inc. since May 7, 2003 and also served as its Senior Vice President since May 2005. He served as Senior Vice President, General Counsel and Secretary of Xpedior Incorporated from March 2000 to 2002. Mr. Belbel has gained extensive experience as a Corporate Transactional Lawyer and General Counsel. He served as General Counsel of Programart Corporation from October 1997 to 2000. From March 1997 to October 1997, he served as Corporate Partner with the Boston office of McDermott, Will & Emery from May 1993 to March 1997. He served as Vice President and General Counsel of Astea International Inc. He served as Director of Avalon Pharmaceuticals, Inc. since May 2009. Mr. Belbel holds a Bachelor of Arts degree from Columbia University and a Juris Doctor degree from Boston College Law School.

Dr. David M. Mauney, M.D., has been Executive Vice President and Chief Business Officer of ZIOPHARM Oncology, Inc. since September 28, 2017 and has been its Interim Chief Operating Officer since November 6, 2017. Dr. Mauney joined Harvest Capital Strategies in 2015. He Co-Founded De Novo Ventures in 2000 and served as its Managing Director. Dr. Mauney has been a Venture Capitalist since 1998. Previously, he served as a Partner at Asset Management Ventures, Assets Management Partners L.P., Asset Management Associates 1984, L.P., Asset Management Associates 1989, L.P., Asset Management Associates 1982, L.P., Assets Management Associates 1995, L.P., and Assets Management Partners 2004, L.P. Dr. Mauney served as a Managing Director at Harvest Capital Strategies LLC. Dr. Mauney was also the Lead Partner of Health Care Investments for Asset Management Company. He served as Managing Director of De Novo Ventures, L.P., De Novo Ventures II, L.P. and De Novo Ventures III, L.P. Dr. Mauney also participated in seven financings of technology companies. Previously, he served as the First Employee and Director of Business Development at Foxhollow Technologies, Inc. Dr. Mauney served in product management at Heartport, Inc. He has been a Director of TRIA Beauty, Inc. since April 2007. He serves on the Boards of Simpirica, ProMed, Inc., Articulinx, Inc., Simpirica Spine, Inc., and Spectragenics. Dr. Mauney served as a Director at Applied Spine Technologies Inc., Ventus Medical, Inc., and Napa Medical Systems. Dr. Mauney served as a Director at LuMend, Inc., and FlowMedica, Inc. He served as an Outside Director of CryoVascular Systems, Inc. Dr. Mauney served as a Director of Paracor Medical, Inc., VeinRx, Inc., and Rachiotek LLC. He has experience in company operations in addition to his medical background. Dr. Mauney holds an M.D. from The Dartmouth School of Medicine. He holds a B.S. in Psychology and a B.A., both from Duke University.

Geri Bardelli serves as the Vice President, Clinical Operations of Ziopharm Oncology. Geri started at Ziopharm Oncology in November of 2018. Geri currently resides in Greater New York City Area.

Lynn Ferrucci serves as the SVP, Human Resources of Ziopharm Oncology. Lynn started at Ziopharm Oncology in January of 2012. Lynn currently resides in Greater Boston Area.

David Mauney serves as the President of Ziopharm Oncology. David started at Ziopharm Oncology in December of 2018. David currently resides in the Greater Boston Area.

Douglas Pagan serves as the Director of Ziopharm Oncology. Douglas started at Ziopharm Oncology in September of 2018. Douglas currently resides in the Greater Boston Area.

Francois Lebel serves as the Senior Vice President, Clinical Development and Medical Operations of Ziopharm Oncology. Francois started at Ziopharm Oncology in February of 2013. Francois currently resides in the Greater Boston Area.